Effects of Bevacizumab Injection Combined with TACE on Tumor Markers,Angiogenic Factors and Apoptotic Molecules in Patients with Middle to Late Stage Hepatocellular Carcinoma
Objective:To investigate the effects of bevacizumab injection combined with transcatheter arterial chemoembolization(TACE)on tumor markers,angiogenic factors and apoptotic molecules in patients with middle to late stage hepatocellular carcinoma(HCC).Methods:Random number table method was used,142 patients with middle to late stage HCC who were admitted to our hospital from September 2021 to April 2023 were divided into control group(n=71,TACE treatment)and study group(n=71,bevacizumab injec-tion combine with TACE treatment).The efficacy,serum tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),α-L-fucosidase(AFU),carbohydrate antigen 19-9(CA19-9)],angiogenesis factors[hepatocyte growth factor(HGF),vascular endothelial growth factor(VEGF),connective tissue growth factor(CTGF),hypoxia-inducible factor-1α(HIF-1α)]and apoptotic molecules[B-cell lymphoma-2(Bcl-2),Bcl-2 associated X protein gene(Bax),survivin(Survivin),C-cysteine-aspartate protease 10(Caspase 10)]were compared between two groups,the incidence of adverse reactions in two groups was observed.Results:The objective response rate(ORR)and disease control rate(DCR)in study group were significantly higher than those in control group(P＜0.05).6 weeks after treat-ment,AFP,CEA,AFU,CA19-9,HGF,VEGF,CTGF,HIF-1α,Bcl-2 and Survivin in two groups decreased,Bax and Caspase 10 in two groups increased,and the improvement in the study group was greater than that in the control group(P＜0.05).The incidence of adverse reactions in the control group was 12.69％,while in the study group was 19.73％,there was no significant difference between the groups(P＞0.05).Conclusion:The combination of bevacizumab injection and TACE in the treatment of advanced HCC patients can effectively reduce tumor marker levels,reduce angiogenesis,and promote HCC cancer cell apoptosis.
Bevacizumab injectionTranscatheter arterial chemoembolizationMiddle to late stage hepatocellular carcinomaTumor markersAngiogenetic factorsApoptosis molecules
NETL
NSTL
万方数据
